Skip to main content
Shanghai Kaibao Pharmaceutical Co.,Ltd. logo

Shanghai Kaibao Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300039 ISIN · CNE100000JZ3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,413 across all filing types
Latest filing 2026-05-21 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300039

About Shanghai Kaibao Pharmaceutical Co.,Ltd.

https://www.xykb.com

Shanghai Kaibao Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of integrated medical solutions, with a primary focus on the modernization of Traditional Chinese Medicine (TCM) and the production of chemical and biological drugs. The company’s flagship product, Tanreqing Injection, is a widely recognized treatment for respiratory tract infections, utilized for its heat-clearing and detoxifying properties. Its broader portfolio encompasses therapeutic solutions for cardiovascular health and respiratory diseases. Shanghai Kaibao operates advanced manufacturing facilities and maintains a robust R&D pipeline dedicated to innovating drug delivery systems and enhancing the clinical efficacy of natural compounds. Through proprietary extraction technologies and rigorous quality control, the firm provides specialized therapeutic options designed to address complex clinical requirements.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement detailing the company’s 2025 annual profit distribution (cash dividend per 10 shares), including the dividend rate, record date, ex‐dividend date, distribution method, and related procedures. This is a Notice of Dividend Amount rather than an annual report or other regulatory filing.
2026-05-21 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the resolutions and detailed voting results from the 2025 Annual General Meeting of Shanghai Kaibao Pharmaceutical Co., Ltd. It lists each proposal, the number of votes for, against, and abstentions, and confirms the validity of the meeting and voting procedures. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 Chinese
上海市通力律师事务所关于上海凯宝2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a legal opinion letter from a law firm concerning the company’s 2025 annual general meeting. It verifies the convening procedures, attendance, voting mechanisms, and then provides detailed vote tallies for each resolution (number of shares for, against, abstained and percentages). This is an official declaration of shareholder voting results at an AGM. Therefore, it best fits the “Declaration of Voting Results & Voting Rights Announcements (DVA)” category.
2026-05-20 Chinese
内部审计制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled '内部审计制度' which translates to 'Internal Audit System' or 'Internal Audit Policy' of Shanghai Kaibao Pharmaceutical Co., Ltd. It details the internal audit framework, responsibilities, procedures, and governance related to internal auditing within the company. It references relevant laws and regulations, the structure and duties of the audit committee and internal audit department, and procedures for internal control evaluation and reporting. The document is a policy or governance document related to internal audit and internal control systems rather than a financial report, earnings release, or announcement. It is not a standalone audit report with audit opinions on financial statements, nor is it an announcement or a brief summary. It fits best under Governance Information (CGR) as it details the company's internal rules and governance practices related to internal audit and control.
2025-10-28 Chinese
第六届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 11th meeting of the 6th Board of Directors of Shanghai Kaibao Pharmaceutical Co., Ltd. It includes approval of the 2025 Q3 report, profit distribution plan, amendments to the company charter, and governance system revisions. The document states that detailed content is available on the designated disclosure website, indicating this is a summary announcement rather than the full report. The document length is 3045 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on board decisions and governance matters, including amendments to governance documents and scheduling a shareholders meeting. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. It is not a full financial report (10-K or IR), nor a proxy statement or voting results announcement. Therefore, the best classification is MANG with high confidence.
2025-10-28 Chinese
2025年第三季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (365 characters) indicating that the company Shanghai Kaibao Pharmaceutical Co., Ltd. has disclosed its 2025 third quarter report on a regulatory website. It states the report was approved by the board and is available for investors to review. The text does not contain the actual financial data or detailed report content but merely informs about the report's publication and availability. According to the 'MENU VS MEAL' rule, such a brief notice announcing the release of a report is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2025-10-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.